Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection-Reference-Cited by-同舟云学术

Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection

Published:2014-02-04 Issue:2 Volume:9 Page:e87572
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Zolla-Pazner Susan,deCamp Allan,Gilbert Peter B.,Williams Constance,Yates Nicole L.,Williams William T.,Howington Robert,Fong Youyi,Morris Daryl E.,Soderberg Kelly A.,Irene Carmela,Reichman Charles,Pinter Abraham,Parks Robert,Pitisuttithum Punnee,Kaewkungwal Jaranit,Rerks-Ngarm Supachai,Nitayaphan Sorachai,Andrews Charla,O’Connell Robert J.,Yang Zhi-yong,Nabel Gary J.,Kim Jerome H.,Michael Nelson L.,Montefiori David C.,Liao Hua-Xin,Haynes Barton F.,Tomaras Georgia D.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference31 articles.

1. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand;S Rerks-Ngarm;N Engl J Med,2009

2. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120;A Pinter;Vaccine,1998

3. Immune Correlates Analysis of the ALVAC-AIDSVAX HIV-1 Vaccine Efficacy Trial;BF Haynes;N Engl J Med,2012

4. Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial;S Zolla-Pazner;PLos One,2013

5. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120;MK Gorny;J Immunol,1993

Cited by 241 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses;Viruses;2024-08-27

2. The effects of high shear rates on the average hydrodynamic diameter measured in biomimetic HIV Gag virus-like particle dispersions;Frontiers in Bioengineering and Biotechnology;2024-05-27

3. Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial;The Lancet HIV;2024-05

4. Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial;PLOS Medicine;2024-03-19

5. Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects;Viruses;2024-02-27